Chronic Iron Overload — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for chronic iron overload. 3 active patents protecting 1 drugs from 1+ originators. First major cliff: 2034. Daily refresh.

1
Approved drugs
3
Active US patents
4/100
Avg vulnerability
—
Annual revenue covered

Originators in Chronic Iron Overload

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Novartis 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating chronic iron overload. Each bar = one year. Y-axis scaled to peak year (3 patents).

3
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Exjade
DEFERASIROX
 Novartis 3 4 — 2034-11-21

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9283209 Exjade composition of matter 4 2034-11-21
9283209 Exjade composition of matter 4 2034-11-21
9283209 Exjade composition of matter 4 2034-11-21

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9283209 Exjade composition of matter 4 2034-11-21
9283209 Exjade composition of matter 4 2034-11-21
9283209 Exjade composition of matter 4 2034-11-21

Related